Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Rocket Pharmaceuticals Inc (Rocket Pharmaceuticals) is a clinical-stage biopharmaceutical company that discovers, develops and commercializes novel gene therapies. The company's pipeline products include AAV RP-A501 which treats danon disease; AAV RP-A601 which targets plakophilin-2 related arrhythmogenic cardiomyopathy; AAV RP-A701 for BCL2-associated athanogene 3 dilated cardiomyopathy; LV RP-L102 which targets fanconi anemia; and LV RP-L301 for pyruvate kinase deficiency. The company offers adeno-associated viral (AAV) vector-based cardiovascular platform and lentiviral (LV) vector-based hematology platform. Rocket Pharmaceuticals is headquartered in Cranbury, New Jersey, the US.
Headquarters
United States of America
Address
9 Cedarbrook Drive, Cranbury, New Jersey, 08512
Website
www.rocketpharma.com
Telephone
1 6464409100
No of Employees
202
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RCKT (NASD)
EPS
XYZ
Net Income (2024)
XYZ
13.8%
(2024 vs 2023)
Market Cap*
$373.4M
* As of and is in US$
Rocket Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | KRESLADIT |
| AAV RP-A501: Danon Disease | |
| AAV RP-A601: Plakophilin-2 Related Arrhythmogenic Cardiomyopathy | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Others | In October, the company received acceptance from the US Food and Drug Administration for KRESLADI (marnetegragene autotemcel; marne-cel), a lentiviral vector-based investigational gene therapy for severe Leukocyte Adhesion Deficiency-I. |
| 2025 | Others | In August, the company announced that the US Food and Drug Administration lifted the clinical hold on the pivotal Phase 2 trial of RP-A501 for the treatment of Danon disease. |
| 2024 | Plans/Strategy | In December, the company announced its plans to sell US$150 million shares in an underwritten public offering. |
Competitor Comparison
| Key Parameters | Rocket Pharmaceuticals Inc | Sarepta Therapeutics Inc | Agios Pharmaceuticals Inc | Jasper Therapeutics Inc | Papillon Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Cranbury | Cambridge | Cambridge | Redwood City | San Diego |
| State/Province | New Jersey | Massachusetts | Massachusetts | California | California |
| No. of Employees | 202 | 835 | 539 | 22 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Roderick Wong, M.D. | Chairman | Executive Board | 2018 | 49 |
| Gaurav Shah, M.D | Director; Chief Executive Officer | Executive Board | 2018 | 51 |
| Christopher Stevens | Chief Operating Officer | Senior Management | 2025 | 46 |
| John Militello | Chief Accounting Officer; Vice President - Finance; Controller; Treasurer | Senior Management | 2018 | 52 |
| Syed Rizvi, MD | Chief Medical Officer | Senior Management | 2025 | 59 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer